# PeptideScanner evidence objects: Zilucoplan

Every published version of the records placed with Zilucoplan, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json. Selected public evidence only; not medical advice.

- Objects: 25
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct04297683-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT04297683

> PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct04297683-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04297683-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct04297683-zilucoplan-v1
- Content SHA-256: `f63cbe3fa445fb323e47bccbda18d415bd98ddf93a51f1548b1dcb8606a05507`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04297683 ([`ctg-observation-nct04297683-2026-07-21-eadcd80fb64a`](#source-ctg-observation-nct04297683-2026-07-21-eadcd80fb64a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct04297683-2026-07-21-eadcd80fb64a`](#source-ctg-observation-nct04297683-2026-07-21-eadcd80fb64a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct04297683-2026-07-21-eadcd80fb64a`](#source-ctg-observation-nct04297683-2026-07-21-eadcd80fb64a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04297683-2026-07-21-eadcd80fb64a`](#source-ctg-observation-nct04297683-2026-07-21-eadcd80fb64a))

### Sources

<a id="source-ctg-observation-nct04297683-2026-07-21-eadcd80fb64a"></a>
- **ClinicalTrials.gov record NCT04297683 · retained source version 2026-07-21:eadcd80fb64abc54edc28b1a1976856f67824c3077203ac4aacdded9f95a6233** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04297683) (`ctg-observation-nct04297683-2026-07-21-eadcd80fb64a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04297683." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct04297683-zilucoplan-v1 SHA-256: f63cbe3fa445fb323e47bccbda18d415bd98ddf93a51f1548b1dcb8606a05507.

---

<a id="clinicaltrials-gov-nct04382755-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT04382755

> PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct04382755-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-09-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04382755-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct04382755-zilucoplan-v1
- Content SHA-256: `225bf897cab99d1b55fd97ef059edc9dce24d16bbd8d55c0bd91579164fcfba2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04382755 ([`ctg-observation-nct04382755-2023-09-14-bdd77568abf9`](#source-ctg-observation-nct04382755-2023-09-14-bdd77568abf9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct04382755-2023-09-14-bdd77568abf9`](#source-ctg-observation-nct04382755-2023-09-14-bdd77568abf9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct04382755-2023-09-14-bdd77568abf9`](#source-ctg-observation-nct04382755-2023-09-14-bdd77568abf9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04382755-2023-09-14-bdd77568abf9`](#source-ctg-observation-nct04382755-2023-09-14-bdd77568abf9))

### Sources

<a id="source-ctg-observation-nct04382755-2023-09-14-bdd77568abf9"></a>
- **ClinicalTrials.gov record NCT04382755 · retained source version 2023-09-14:bdd77568abf972cb0abf5df78a57d945a19ff2523b7142ad953d4df2f5c77266** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04382755) (`ctg-observation-nct04382755-2023-09-14-bdd77568abf9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04382755." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct04382755-zilucoplan-v1 SHA-256: 225bf897cab99d1b55fd97ef059edc9dce24d16bbd8d55c0bd91579164fcfba2.

---

<a id="clinicaltrials-gov-nct04436497-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT04436497

> PeptideScanner retained ClinicalTrials.gov record NCT04436497 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-07-25, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct04436497-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04436497-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct04436497-zilucoplan-v1
- Content SHA-256: `c6a96da16a00a61410efc2da8afcfd8afb94cf203a3e516308763c55a0383884`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04436497 ([`ctg-observation-nct04436497-2023-07-25-52f518fe3b98`](#source-ctg-observation-nct04436497-2023-07-25-52f518fe3b98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04436497 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-07-25, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct04436497-2023-07-25-52f518fe3b98`](#source-ctg-observation-nct04436497-2023-07-25-52f518fe3b98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04436497 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-07-25, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct04436497-2023-07-25-52f518fe3b98`](#source-ctg-observation-nct04436497-2023-07-25-52f518fe3b98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04436497-2023-07-25-52f518fe3b98`](#source-ctg-observation-nct04436497-2023-07-25-52f518fe3b98))

### Sources

<a id="source-ctg-observation-nct04436497-2023-07-25-52f518fe3b98"></a>
- **ClinicalTrials.gov record NCT04436497 · retained source version 2023-07-25:52f518fe3b98c9c292169b9fdf52ad6ec0b240dadb4104a7830d4bc4d823b313** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04436497) (`ctg-observation-nct04436497-2023-07-25-52f518fe3b98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04436497." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct04436497-zilucoplan-v1 SHA-256: c6a96da16a00a61410efc2da8afcfd8afb94cf203a3e516308763c55a0383884.

---

<a id="clinicaltrials-gov-nct04590586-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT04590586

> PeptideScanner retained ClinicalTrials.gov record NCT04590586 at 2026-11-15T21:46:36.651Z. Its registry update date was 2022-06-29, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct04590586-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-06-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04590586-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct04590586-zilucoplan-v1
- Content SHA-256: `4bdf9aab005f99b2ccd88e9fa9f40f526d9a90ca0975ce3a4ed374d119b3ffc1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04590586 ([`ctg-observation-nct04590586-2022-06-29-bf843cce8276`](#source-ctg-observation-nct04590586-2022-06-29-bf843cce8276))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04590586 at 2026-11-15T21:46:36.651Z. Its registry update date was 2022-06-29, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct04590586-2022-06-29-bf843cce8276`](#source-ctg-observation-nct04590586-2022-06-29-bf843cce8276))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04590586 at 2026-11-15T21:46:36.651Z. Its registry update date was 2022-06-29, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct04590586-2022-06-29-bf843cce8276`](#source-ctg-observation-nct04590586-2022-06-29-bf843cce8276))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04590586-2022-06-29-bf843cce8276`](#source-ctg-observation-nct04590586-2022-06-29-bf843cce8276))

### Sources

<a id="source-ctg-observation-nct04590586-2022-06-29-bf843cce8276"></a>
- **ClinicalTrials.gov record NCT04590586 · retained source version 2022-06-29:bf843cce8276ebf7acb07ce22154c343cc816109e1461ead6fc2a74825ae0841** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04590586) (`ctg-observation-nct04590586-2022-06-29-bf843cce8276`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04590586." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct04590586-zilucoplan-v1 SHA-256: 4bdf9aab005f99b2ccd88e9fa9f40f526d9a90ca0975ce3a4ed374d119b3ffc1.

---

<a id="clinicaltrials-gov-nct06055959-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT06055959

> PeptideScanner retained ClinicalTrials.gov record NCT06055959 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct06055959-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06055959-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06055959-zilucoplan-v1
- Content SHA-256: `e30b80883410e47f13e1c8e67189a23c7b69111839e684c13686d1ae92dc67fb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06055959 ([`ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d`](#source-ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06055959 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d`](#source-ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06055959 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d`](#source-ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d`](#source-ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d))

### Sources

<a id="source-ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d"></a>
- **ClinicalTrials.gov record NCT06055959 · retained source version 2026-11-05:a0fcfb474a6db673f21f12528f6e8b1410ea8e7e8300cb0e53c7e3ef119a7b95** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06055959) (`ctg-observation-nct06055959-2026-11-05-a0fcfb474a6d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06055959." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06055959-zilucoplan-v1 SHA-256: e30b80883410e47f13e1c8e67189a23c7b69111839e684c13686d1ae92dc67fb.

---

<a id="clinicaltrials-gov-nct06435312-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT06435312

> PeptideScanner retained ClinicalTrials.gov record NCT06435312 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct06435312-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06435312-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06435312-zilucoplan-v1
- Content SHA-256: `a42fcd3d04b515e0af6624d56ac315f5506e212d96d62d7aaa66a5740e62dd92`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06435312 ([`ctg-observation-nct06435312-2026-10-02-aab7f4764849`](#source-ctg-observation-nct06435312-2026-10-02-aab7f4764849))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06435312 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06435312-2026-10-02-aab7f4764849`](#source-ctg-observation-nct06435312-2026-10-02-aab7f4764849))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06435312 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06435312-2026-10-02-aab7f4764849`](#source-ctg-observation-nct06435312-2026-10-02-aab7f4764849))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06435312-2026-10-02-aab7f4764849`](#source-ctg-observation-nct06435312-2026-10-02-aab7f4764849))

### Sources

<a id="source-ctg-observation-nct06435312-2026-10-02-aab7f4764849"></a>
- **ClinicalTrials.gov record NCT06435312 · retained source version 2026-10-02:aab7f4764849b5f7050ca30fc50f876ac571a8baa3024ae7099b1fd74be50f3f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06435312) (`ctg-observation-nct06435312-2026-10-02-aab7f4764849`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06435312." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06435312-zilucoplan-v1 SHA-256: a42fcd3d04b515e0af6624d56ac315f5506e212d96d62d7aaa66a5740e62dd92.

---

<a id="clinicaltrials-gov-nct06471361-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT06471361

> PeptideScanner retained ClinicalTrials.gov record NCT06471361 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct06471361-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06471361-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06471361-zilucoplan-v1
- Content SHA-256: `b746c701aaae1bb866563292d754c3a736db240c70d9f3032a49898d3e052a09`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06471361 ([`ctg-observation-nct06471361-2026-03-27-f455ef70d83f`](#source-ctg-observation-nct06471361-2026-03-27-f455ef70d83f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06471361 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06471361-2026-03-27-f455ef70d83f`](#source-ctg-observation-nct06471361-2026-03-27-f455ef70d83f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06471361 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06471361-2026-03-27-f455ef70d83f`](#source-ctg-observation-nct06471361-2026-03-27-f455ef70d83f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06471361-2026-03-27-f455ef70d83f`](#source-ctg-observation-nct06471361-2026-03-27-f455ef70d83f))

### Sources

<a id="source-ctg-observation-nct06471361-2026-03-27-f455ef70d83f"></a>
- **ClinicalTrials.gov record NCT06471361 · retained source version 2026-03-27:f455ef70d83f6776c707610ecee7c65e07f4f2524e5fdc95991862de74d1aa53** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06471361) (`ctg-observation-nct06471361-2026-03-27-f455ef70d83f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06471361." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06471361-zilucoplan-v1 SHA-256: b746c701aaae1bb866563292d754c3a736db240c70d9f3032a49898d3e052a09.

---

<a id="clinicaltrials-gov-nct06511076-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT06511076

> PeptideScanner retained ClinicalTrials.gov record NCT06511076 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct06511076-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06511076-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06511076-zilucoplan-v1
- Content SHA-256: `85311181b5f14e2690216b67b972079856bcf405a77f67e5e40ea01c0c6be7f4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06511076 ([`ctg-observation-nct06511076-2026-01-06-dc87452f3385`](#source-ctg-observation-nct06511076-2026-01-06-dc87452f3385))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06511076 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06511076-2026-01-06-dc87452f3385`](#source-ctg-observation-nct06511076-2026-01-06-dc87452f3385))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06511076 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06511076-2026-01-06-dc87452f3385`](#source-ctg-observation-nct06511076-2026-01-06-dc87452f3385))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06511076-2026-01-06-dc87452f3385`](#source-ctg-observation-nct06511076-2026-01-06-dc87452f3385))

### Sources

<a id="source-ctg-observation-nct06511076-2026-01-06-dc87452f3385"></a>
- **ClinicalTrials.gov record NCT06511076 · retained source version 2026-01-06:dc87452f3385925d89b182e0eaf73fcb00599c2012be4b41c83dac17152c4607** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06511076) (`ctg-observation-nct06511076-2026-01-06-dc87452f3385`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06511076." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06511076-zilucoplan-v1 SHA-256: 85311181b5f14e2690216b67b972079856bcf405a77f67e5e40ea01c0c6be7f4.

---

<a id="clinicaltrials-gov-nct06815133-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT06815133

> PeptideScanner retained ClinicalTrials.gov record NCT06815133 at 2026-11-15T21:46:36.651Z. Its registry update date was 2025-12-03, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct06815133-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06815133-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06815133-zilucoplan-v1
- Content SHA-256: `b01866c2f99a5ac27bb335e2643f6821dab014a823d43ab4db74ac04e97160de`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06815133 ([`ctg-observation-nct06815133-2025-12-03-ac4823067a3a`](#source-ctg-observation-nct06815133-2025-12-03-ac4823067a3a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06815133 at 2026-11-15T21:46:36.651Z. Its registry update date was 2025-12-03, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06815133-2025-12-03-ac4823067a3a`](#source-ctg-observation-nct06815133-2025-12-03-ac4823067a3a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06815133 at 2026-11-15T21:46:36.651Z. Its registry update date was 2025-12-03, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06815133-2025-12-03-ac4823067a3a`](#source-ctg-observation-nct06815133-2025-12-03-ac4823067a3a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06815133-2025-12-03-ac4823067a3a`](#source-ctg-observation-nct06815133-2025-12-03-ac4823067a3a))

### Sources

<a id="source-ctg-observation-nct06815133-2025-12-03-ac4823067a3a"></a>
- **ClinicalTrials.gov record NCT06815133 · retained source version 2025-12-03:ac4823067a3ae20a86abc485b45e9f96492aebb393e5ce66bad9e9e1cce19e52** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06815133) (`ctg-observation-nct06815133-2025-12-03-ac4823067a3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06815133." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06815133-zilucoplan-v1 SHA-256: b01866c2f99a5ac27bb335e2643f6821dab014a823d43ab4db74ac04e97160de.

---

<a id="clinicaltrials-gov-nct06961747-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT06961747

> PeptideScanner retained ClinicalTrials.gov record NCT06961747 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct06961747-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06961747-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06961747-zilucoplan-v1
- Content SHA-256: `e8b8a553fe10b453fc33c2045a74ce17cb3d88f0add3dd9c5762f5d379860764`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06961747 ([`ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30`](#source-ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06961747 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30`](#source-ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06961747 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30`](#source-ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30`](#source-ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30))

### Sources

<a id="source-ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30"></a>
- **ClinicalTrials.gov record NCT06961747 · retained source version 2026-08-27:aa8dd2ce3d306362bebca65f265e72aa5ceca361c39ca283e99dffbf4d6baa3e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06961747) (`ctg-observation-nct06961747-2026-08-27-aa8dd2ce3d30`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06961747." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct06961747-zilucoplan-v1 SHA-256: e8b8a553fe10b453fc33c2045a74ce17cb3d88f0add3dd9c5762f5d379860764.

---

<a id="clinicaltrials-gov-nct07215949-zilucoplan-v1"></a>

## ClinicalTrials.gov record NCT07215949

> PeptideScanner retained ClinicalTrials.gov record NCT07215949 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was zilucoplan.

- Evidence object: `story:clinicaltrials-gov-nct07215949-zilucoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07215949-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct07215949-zilucoplan-v1
- Content SHA-256: `0e6f2b011bc8c1c00f61c72f52fb23c546f2aad91a9ef89eb42245241c786385`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07215949 ([`ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c`](#source-ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07215949 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c`](#source-ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07215949 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was zilucoplan. ([`ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c`](#source-ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c`](#source-ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c))

### Sources

<a id="source-ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c"></a>
- **ClinicalTrials.gov record NCT07215949 · retained source version 2026-08-28:a1e11ef10e8c535055e9bf4d69b85edc81a5c16793bdcb902123f64dc5f4db7b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07215949) (`ctg-observation-nct07215949-2026-08-28-a1e11ef10e8c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07215949." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#clinicaltrials-gov-nct07215949-zilucoplan-v1 SHA-256: 0e6f2b011bc8c1c00f61c72f52fb23c546f2aad91a9ef89eb42245241c786385.

---

<a id="fda-drugs-nda216834-v1"></a>

## Drugs@FDA application NDA216834

> The official Drugs@FDA dataset lists original submission 1 for NDA 216834 with status AP dated 2023-10-17, and names zilucoplan sodium among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda216834:v1`
- Evidence domain: Regulatory
- Date in source: 2023-10-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda216834/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#fda-drugs-nda216834-v1
- Content SHA-256: `27867bbc1b03dbf66567de3e03a6caf44aab270c18e4d9eb987aeabd7898a9cd`

### Claims and source pins

#### Headline

Drugs@FDA application NDA216834 ([`fda-drugs-nda216834-2023-10-17-426536793db5`](#source-fda-drugs-nda216834-2023-10-17-426536793db5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 216834 with status AP dated 2023-10-17, and names zilucoplan sodium among the application record's active ingredients. ([`fda-drugs-nda216834-2023-10-17-426536793db5`](#source-fda-drugs-nda216834-2023-10-17-426536793db5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 216834 with status AP dated 2023-10-17, and names zilucoplan sodium among the application record's active ingredients. ([`fda-drugs-nda216834-2023-10-17-426536793db5`](#source-fda-drugs-nda216834-2023-10-17-426536793db5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda216834-2023-10-17-426536793db5`](#source-fda-drugs-nda216834-2023-10-17-426536793db5))

### Sources

<a id="source-fda-drugs-nda216834-2023-10-17-426536793db5"></a>
- **Drugs@FDA application NDA216834 · original submission status AP · 2023-10-17 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA216834%22&limit=1) (`fda-drugs-nda216834-2023-10-17-426536793db5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA216834." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#fda-drugs-nda216834-v1 SHA-256: 27867bbc1b03dbf66567de3e03a6caf44aab270c18e4d9eb987aeabd7898a9cd.

---

<a id="federal-register-2025-09068-v1"></a>

## Federal Register notice 2025-09068

> The Federal Register published notice 2025-09068, attributed to FDA and its parent HHS department, on 2025-05-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan.

- Evidence object: `story:federal-register-2025-09068:v1`
- Evidence domain: Regulatory
- Date in source: 2025-05-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-09068/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#federal-register-2025-09068-v1
- Content SHA-256: `de399457b1a4420d01eff3dde157334d8bf1a9406b66f2c05f2f0e2059839fa6`

### Claims and source pins

#### Headline

Federal Register notice 2025-09068 ([`federal-register-2025-09068-d358a6662c3d`](#source-federal-register-2025-09068-d358a6662c3d))

#### Summary

The Federal Register published notice 2025-09068, attributed to FDA and its parent HHS department, on 2025-05-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan. ([`federal-register-2025-09068-d358a6662c3d`](#source-federal-register-2025-09068-d358a6662c3d))

#### Paragraph 1

The Federal Register published notice 2025-09068, attributed to FDA and its parent HHS department, on 2025-05-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan. ([`federal-register-2025-09068-d358a6662c3d`](#source-federal-register-2025-09068-d358a6662c3d))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-09068-d358a6662c3d`](#source-federal-register-2025-09068-d358a6662c3d))

### Sources

<a id="source-federal-register-2025-09068-d358a6662c3d"></a>
- **Federal Register notice 2025-09068 · published 2025-05-21 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-05-21/pdf/2025-09068.pdf) (`federal-register-2025-09068-d358a6662c3d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-09068." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#federal-register-2025-09068-v1 SHA-256: de399457b1a4420d01eff3dde157334d8bf1a9406b66f2c05f2f0e2059839fa6.

---

<a id="federal-register-2025-11314-v1"></a>

## Federal Register notice 2025-11314

> The Federal Register published notice 2025-11314, attributed to FDA and its parent HHS department, on 2025-06-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZILBRYSQ,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan.

- Evidence object: `story:federal-register-2025-11314:v1`
- Evidence domain: Regulatory
- Date in source: 2025-06-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-11314/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#federal-register-2025-11314-v1
- Content SHA-256: `791471c5ec326efeb415f43a7efe462f18ba17a69015f3b5ef5d6f79f5be874b`

### Claims and source pins

#### Headline

Federal Register notice 2025-11314 ([`federal-register-2025-11314-576f78360535`](#source-federal-register-2025-11314-576f78360535))

#### Summary

The Federal Register published notice 2025-11314, attributed to FDA and its parent HHS department, on 2025-06-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZILBRYSQ,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan. ([`federal-register-2025-11314-576f78360535`](#source-federal-register-2025-11314-576f78360535))

#### Paragraph 1

The Federal Register published notice 2025-11314, attributed to FDA and its parent HHS department, on 2025-06-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZILBRYSQ,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan. ([`federal-register-2025-11314-576f78360535`](#source-federal-register-2025-11314-576f78360535))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-11314-576f78360535`](#source-federal-register-2025-11314-576f78360535))

### Sources

<a id="source-federal-register-2025-11314-576f78360535"></a>
- **Federal Register notice 2025-11314 · published 2025-06-20 · Determination of Regulatory Review Period for Purposes of Patent Extension; ZILBRYSQ** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-06-20/pdf/2025-11314.pdf) (`federal-register-2025-11314-576f78360535`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-11314." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#federal-register-2025-11314-v1 SHA-256: 791471c5ec326efeb415f43a7efe462f18ba17a69015f3b5ef5d6f79f5be874b.

---

<a id="pubmed-pmid-33398524-zilucoplan-v1"></a>

## Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan.

> PubMed lists PMID 33398524 in Amino acids as Journal Article, with publication-date metadata of 2021-01-04 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33398524-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33398524-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-33398524-zilucoplan-v1
- Content SHA-256: `168c53240575c137fc5c60cd3956d929ea3b30b22b59c21d83913f3efc9a5c11`

### Claims and source pins

#### Headline

Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. ([`pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322`](#source-pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322))

#### Summary

PubMed lists PMID 33398524 in Amino acids as Journal Article, with publication-date metadata of 2021-01-04 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322`](#source-pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322))

#### Paragraph 1

PubMed lists PMID 33398524 in Amino acids as Journal Article, with publication-date metadata of 2021-01-04 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322`](#source-pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322`](#source-pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322))

### Sources

<a id="source-pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322"></a>
- **Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. · retained source version 1:2021-12-20:current:f8aa51f593228f645a83ad5004f6efd61a756a3b5fa5896375c7db91be0c3e17** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33398524/) (`pubmed-observation-pmid-33398524-2021-12-20-f8aa51f59322`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-33398524-zilucoplan-v1 SHA-256: 168c53240575c137fc5c60cd3956d929ea3b30b22b59c21d83913f3efc9a5c11.

---

<a id="pubmed-pmid-37534517-zilucoplan-v1"></a>

## Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.

> PubMed lists PMID 37534517 in Haematologica as Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-03-01 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37534517-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-08-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37534517-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-37534517-zilucoplan-v1
- Content SHA-256: `7384e61655c3c22ede51c425696ae9aa8b394d42d79f5ca23d12b18962949451`

### Claims and source pins

#### Headline

Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria. ([`pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664`](#source-pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664))

#### Summary

PubMed lists PMID 37534517 in Haematologica as Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-03-01 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664`](#source-pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664))

#### Paragraph 1

PubMed lists PMID 37534517 in Haematologica as Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-03-01 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664`](#source-pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664`](#source-pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664))

### Sources

<a id="source-pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664"></a>
- **Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria. · retained source version 1:2024-08-16:current:db389e4e0664492de32fbc3172eb27d1942e47c053732b0e700a8e87b92de717** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37534517/) (`pubmed-observation-pmid-37534517-2024-08-16-db389e4e0664`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-37534517-zilucoplan-v1 SHA-256: 7384e61655c3c22ede51c425696ae9aa8b394d42d79f5ca23d12b18962949451.

---

<a id="pubmed-pmid-38576149-zilucoplan-v1"></a>

## Zilucoplan (Zilbrysq) for myasthenia gravis.

> PubMed lists PMID 38576149 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38576149-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-04-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38576149-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-38576149-zilucoplan-v1
- Content SHA-256: `29ccb4c4eae4cd623c0080dac20daac024535de9173f423bbd3d4483f90a136d`

### Claims and source pins

#### Headline

Zilucoplan (Zilbrysq) for myasthenia gravis. ([`pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8`](#source-pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8))

#### Summary

PubMed lists PMID 38576149 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8`](#source-pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8))

#### Paragraph 1

PubMed lists PMID 38576149 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8`](#source-pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8`](#source-pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8))

### Sources

<a id="source-pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8"></a>
- **Zilucoplan (Zilbrysq) for myasthenia gravis. · retained source version 1:2024-04-08:current:14f7d8abd3b8c959e085e6cf3cc7feedf090ebc1f4299e7bc7b3eb832b617913** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38576149/) (`pubmed-observation-pmid-38576149-2024-04-08-14f7d8abd3b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Zilucoplan (Zilbrysq) for myasthenia gravis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-38576149-zilucoplan-v1 SHA-256: 29ccb4c4eae4cd623c0080dac20daac024535de9173f423bbd3d4483f90a136d.

---

<a id="pubmed-pmid-39403865-zilucoplan-v1"></a>

## Usability of the zilucoplan prefilled syringe for the treatment of generalized myasthenia gravis: insights from a human factors validation study.

> PubMed lists PMID 39403865 in Expert review of medical devices as Journal Article, Validation Study, with publication-date metadata of 2024-10-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39403865-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-10-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39403865-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-39403865-zilucoplan-v1
- Content SHA-256: `3d6dd41f46b2877e47e17372ca112f47f04390eb51f118fabb4a44363a02209e`

### Claims and source pins

#### Headline

Usability of the zilucoplan prefilled syringe for the treatment of generalized myasthenia gravis: insights from a human factors validation study. ([`pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38`](#source-pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38))

#### Summary

PubMed lists PMID 39403865 in Expert review of medical devices as Journal Article, Validation Study, with publication-date metadata of 2024-10-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38`](#source-pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38))

#### Paragraph 1

PubMed lists PMID 39403865 in Expert review of medical devices as Journal Article, Validation Study, with publication-date metadata of 2024-10-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38`](#source-pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38`](#source-pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38))

### Sources

<a id="source-pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38"></a>
- **Usability of the zilucoplan prefilled syringe for the treatment of generalized myasthenia gravis: insights from a human factors validation study. · retained source version 1:2024-10-15:current:3edc7665ee389ebe5aad49d0db387b0bc83b990db439ee47dc9305b9bece1c08** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39403865/) (`pubmed-observation-pmid-39403865-2024-10-15-3edc7665ee38`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Usability of the zilucoplan prefilled syringe for the treatment of generalized myasthenia gravis: insights from a human factors validation study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-39403865-zilucoplan-v1 SHA-256: 3d6dd41f46b2877e47e17372ca112f47f04390eb51f118fabb4a44363a02209e.

---

<a id="pubmed-pmid-40685269-zilucoplan-v1"></a>

## Zilucoplan as a fast-acting treatment for severe myasthenic exacerbation: A case series.

> PubMed lists PMID 40685269 in Revue neurologique as Letter, with publication-date metadata of 2025-07-19 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40685269-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40685269-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-40685269-zilucoplan-v1
- Content SHA-256: `44fcb43020774b0597d1d0673857c13d1ac82faef04511dff7a2aa40459e22e8`

### Claims and source pins

#### Headline

Zilucoplan as a fast-acting treatment for severe myasthenic exacerbation: A case series. ([`pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32`](#source-pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32))

#### Summary

PubMed lists PMID 40685269 in Revue neurologique as Letter, with publication-date metadata of 2025-07-19 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32`](#source-pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32))

#### Paragraph 1

PubMed lists PMID 40685269 in Revue neurologique as Letter, with publication-date metadata of 2025-07-19 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32`](#source-pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32`](#source-pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32))

### Sources

<a id="source-pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32"></a>
- **Zilucoplan as a fast-acting treatment for severe myasthenic exacerbation: A case series. · retained source version 1:2025-09-11:current:af3502c01a3215506d0bf26fe211461f5fc9e3d0cb7a0b322bfb4b6696291ac5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40685269/) (`pubmed-observation-pmid-40685269-2025-09-11-af3502c01a32`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Zilucoplan as a fast-acting treatment for severe myasthenic exacerbation: A case series." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-40685269-zilucoplan-v1 SHA-256: 44fcb43020774b0597d1d0673857c13d1ac82faef04511dff7a2aa40459e22e8.

---

<a id="pubmed-pmid-41058183-zilucoplan-v1"></a>

## Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan.

> PubMed lists PMID 41058183 in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG as Case Reports, Journal Article, with publication-date metadata of 2025-10-07 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41058183-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-02-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41058183-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-41058183-zilucoplan-v1
- Content SHA-256: `5d34b52db9c29a2ba6745179ecf69d5d8e5eaf6039d928c3f0c74c85d1704e19`

### Claims and source pins

#### Headline

Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan. ([`pubmed-observation-pmid-41058183-2026-02-07-6885b5438030`](#source-pubmed-observation-pmid-41058183-2026-02-07-6885b5438030))

#### Summary

PubMed lists PMID 41058183 in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG as Case Reports, Journal Article, with publication-date metadata of 2025-10-07 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41058183-2026-02-07-6885b5438030`](#source-pubmed-observation-pmid-41058183-2026-02-07-6885b5438030))

#### Paragraph 1

PubMed lists PMID 41058183 in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG as Case Reports, Journal Article, with publication-date metadata of 2025-10-07 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41058183-2026-02-07-6885b5438030`](#source-pubmed-observation-pmid-41058183-2026-02-07-6885b5438030))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41058183-2026-02-07-6885b5438030`](#source-pubmed-observation-pmid-41058183-2026-02-07-6885b5438030))

### Sources

<a id="source-pubmed-observation-pmid-41058183-2026-02-07-6885b5438030"></a>
- **Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan. · retained source version 1:2026-02-07:current:6885b5438030d3f009c5350bea2bd24c3ae9bac1610818605ace02139a7d1b75** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41058183/) (`pubmed-observation-pmid-41058183-2026-02-07-6885b5438030`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-41058183-zilucoplan-v1 SHA-256: 5d34b52db9c29a2ba6745179ecf69d5d8e5eaf6039d928c3f0c74c85d1704e19.

---

<a id="pubmed-pmid-41314023-zilucoplan-v1"></a>

## Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

> PubMed lists PMID 41314023 in Journal of the neurological sciences as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41314023-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41314023-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-41314023-zilucoplan-v1
- Content SHA-256: `eee6c72c483a5e36b2460a9ec0b716f881a47f97aab3c10ed3b7a79b64ec2ca6`

### Claims and source pins

#### Headline

Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. ([`pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405`](#source-pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405))

#### Summary

PubMed lists PMID 41314023 in Journal of the neurological sciences as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405`](#source-pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405))

#### Paragraph 1

PubMed lists PMID 41314023 in Journal of the neurological sciences as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405`](#source-pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405`](#source-pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405))

### Sources

<a id="source-pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405"></a>
- **Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. · retained source version 1:2026-05-01:current:8f05fae5c4055488879e12e8e4d72529dac9eef31521102b909f84a288647c10** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41314023/) (`pubmed-observation-pmid-41314023-2026-05-01-8f05fae5c405`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-41314023-zilucoplan-v1 SHA-256: eee6c72c483a5e36b2460a9ec0b716f881a47f97aab3c10ed3b7a79b64ec2ca6.

---

<a id="pubmed-pmid-41604997-zilucoplan-v1"></a>

## Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

> PubMed lists PMID 41604997 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-23 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41604997-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-02-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41604997-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-41604997-zilucoplan-v1
- Content SHA-256: `10ac636c5827e34ee7e2bc429f3b712ceb385ee97efa5e95f9ebaf42dd38a468`

### Claims and source pins

#### Headline

Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. ([`pubmed-observation-pmid-41604997-2026-02-23-873d567165e8`](#source-pubmed-observation-pmid-41604997-2026-02-23-873d567165e8))

#### Summary

PubMed lists PMID 41604997 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-23 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41604997-2026-02-23-873d567165e8`](#source-pubmed-observation-pmid-41604997-2026-02-23-873d567165e8))

#### Paragraph 1

PubMed lists PMID 41604997 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-23 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41604997-2026-02-23-873d567165e8`](#source-pubmed-observation-pmid-41604997-2026-02-23-873d567165e8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41604997-2026-02-23-873d567165e8`](#source-pubmed-observation-pmid-41604997-2026-02-23-873d567165e8))

### Sources

<a id="source-pubmed-observation-pmid-41604997-2026-02-23-873d567165e8"></a>
- **Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. · retained source version 1:2026-02-23:current:873d567165e899cd1c0a6ee074da087b43661135d8d4722e3d7ec16606a35904** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41604997/) (`pubmed-observation-pmid-41604997-2026-02-23-873d567165e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-41604997-zilucoplan-v1 SHA-256: 10ac636c5827e34ee7e2bc429f3b712ceb385ee97efa5e95f9ebaf42dd38a468.

---

<a id="pubmed-pmid-41653661-zilucoplan-v1"></a>

## Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

> PubMed lists PMID 41653661 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-22 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41653661-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-02-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41653661-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-41653661-zilucoplan-v1
- Content SHA-256: `08b2580dba11117aafac42cb1967d697fa669cbc58911c958fd4d602bd5a17d3`

### Claims and source pins

#### Headline

Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. ([`pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a`](#source-pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a))

#### Summary

PubMed lists PMID 41653661 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-22 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a`](#source-pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a))

#### Paragraph 1

PubMed lists PMID 41653661 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-22 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a`](#source-pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a`](#source-pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a))

### Sources

<a id="source-pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a"></a>
- **Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. · retained source version 1:2026-02-23:current:801abd8a5d1adeacc2080d8db425bafcf1c1b4b732e5a2d3e4028077f836ba0a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41653661/) (`pubmed-observation-pmid-41653661-2026-02-23-801abd8a5d1a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-41653661-zilucoplan-v1 SHA-256: 08b2580dba11117aafac42cb1967d697fa669cbc58911c958fd4d602bd5a17d3.

---

<a id="pubmed-pmid-42467314-zilucoplan-v1"></a>

## Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.

> PubMed lists PMID 42467314 in Acta neurologica Belgica as Letter, with publication-date metadata of 2026-07-17 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42467314-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42467314-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-42467314-zilucoplan-v1
- Content SHA-256: `ce2c96179ff255a7b62c15eee94ed14e7fe6fd3e5a14090d307066140ba8e79b`

### Claims and source pins

#### Headline

Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences. ([`pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33`](#source-pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33))

#### Summary

PubMed lists PMID 42467314 in Acta neurologica Belgica as Letter, with publication-date metadata of 2026-07-17 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33`](#source-pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33))

#### Paragraph 1

PubMed lists PMID 42467314 in Acta neurologica Belgica as Letter, with publication-date metadata of 2026-07-17 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33`](#source-pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33`](#source-pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33))

### Sources

<a id="source-pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33"></a>
- **Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences. · retained source version 1:2026-10-28:current:2703b5407a33f2cb12c882f6b0683a265034baa4e7a28876b0e23ad1ac2a5223** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42467314/) (`pubmed-observation-pmid-42467314-2026-10-28-2703b5407a33`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-42467314-zilucoplan-v1 SHA-256: ce2c96179ff255a7b62c15eee94ed14e7fe6fd3e5a14090d307066140ba8e79b.

---

<a id="pubmed-pmid-42604018-zilucoplan-v1"></a>

## A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.

> PubMed lists PMID 42604018 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42604018-zilucoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42604018-zilucoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-42604018-zilucoplan-v1
- Content SHA-256: `26d9201f0b34136c1fb6c3cd686446add62ecfce8bc3f9bbbc93708c9273edfb`

### Claims and source pins

#### Headline

A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis. ([`pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639`](#source-pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639))

#### Summary

PubMed lists PMID 42604018 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639`](#source-pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639))

#### Paragraph 1

PubMed lists PMID 42604018 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639`](#source-pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639`](#source-pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639))

### Sources

<a id="source-pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639"></a>
- **A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis. · retained source version 1:2026-08-17:current:f383f0b3d6395b7092fe350a8f4383ce5e35d8e5276df3c1e4d1cc801587d30d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42604018/) (`pubmed-observation-pmid-42604018-2026-08-17-f383f0b3d639`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/zilucoplan.json#pubmed-pmid-42604018-zilucoplan-v1 SHA-256: 26d9201f0b34136c1fb6c3cd686446add62ecfce8bc3f9bbbc93708c9273edfb.

